RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesis.
about
Optimization of feline immunodeficiency virus vectors for RNA interferenceInvolvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growthKLF4 is a key determinant in the development and progression of cerebral cavernous malformations.The diacylglycerol kinase α/atypical PKC/β1 integrin pathway in SDF-1α mammary carcinoma invasiveness.PRL-3 siRNA inhibits the metastasis of B16-BL6 mouse melanoma cells in vitro and in vivo.DNA triplex-mediated inhibition of MET leads to cell death and tumor regression in hepatoma.Triggered release of siRNA from poly(ethylene glycol)-protected, pH-dependent liposomesTargeting endothelial junctional adhesion molecule-A/ EPAC/ Rap-1 axis as a novel strategy to increase stem cell engraftment in dystrophic muscles.Inhibiting metastatic breast cancer cell migration via the synergy of targeted, pH-triggered siRNA delivery and chemokine axis blockadeDissecting the transcriptional phenotype of ribosomal protein deficiency: implications for Diamond-Blackfan Anemia.Lack of Diaph3 relaxes the spindle checkpoint causing the loss of neural progenitors.Agonist monoclonal antibodies against HGF receptor protect cardiac muscle cells from apoptosis.Development of a species-specific RNA polymerase I-based shRNA expression vector.Use of herpes simplex virus type 1-based amplicon vector for delivery of small interfering RNA.Curcuminoid-phospholipid complex induces apoptosis in mammary epithelial cells by STAT-3 signaling.Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas.
P2860
Q24671047-470A47AE-D880-49D3-80FE-77BF54FAD245Q30156817-35E4915C-21AA-4368-B2A2-355FD5A22066Q30278010-C0236391-4EF0-4647-9139-B0CAAA86E813Q33699564-46C5CA5E-29F1-42E8-A8B1-024F84D1604FQ35844070-DCF9434B-3FB9-4DE8-AE00-6F0DBBB3ADF1Q36868117-31661AEB-44F7-4B80-A41C-76043192B68BQ37026510-BCB75EA1-3CAE-4919-BA29-CD4CF3C54558Q37591115-6DEF68D4-8F7B-4468-98BD-5C4283EAEE64Q37714248-A1832D30-5400-4F07-9053-229E51CADA16Q38994386-1F8D4B54-0D93-4945-8DF1-A4B4B281A2E9Q39184383-B7C57CE9-BC9A-4829-805C-24BDFC79603AQ39753947-0AA6720B-840E-4FE9-9CF2-D27C9D0216A4Q40198631-03513FBE-E064-406B-A632-B041DA7E58ABQ40218147-42B1FAA8-B6AD-4F37-927F-C3EF35A62CF9Q41843820-EB156870-4D18-4F8B-ABC3-9FDA93BCB7D4Q42004966-F76651AF-4FA3-439C-BA78-CFECFA513383
P2860
RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
RNAi technology and lentiviral ...... pr-Met-mediated tumorigenesis.
@en
type
label
RNAi technology and lentiviral ...... pr-Met-mediated tumorigenesis.
@en
prefLabel
RNAi technology and lentiviral ...... pr-Met-mediated tumorigenesis.
@en
P2093
P2860
P50
P356
P1433
P1476
RNAi technology and lentiviral ...... Tpr-Met-mediated tumorigenesis
@en
P2093
Carola Ponzetto
Claudio Scuoppo
Francesca Bersani
Paolo Accornero
Tony Mangano
P2860
P2888
P304
P356
10.1038/SJ.CGT.7700815
P50
P577
2005-05-01T00:00:00Z
P5875
P6179
1033247476